Oat-Based Postbiotic Keystone Improves Mood & Microbiota: New Trial Data
A recent Verb Biotics trial demonstrates its oat-based postbiotic, Keystone, significantly enriches beneficial gut microbiota, reduces inflammatory markers, and enhances emotional wellness over four weeks. This offers brand owners a novel, targeted ingredient for gut-brain axis formulations without probiotic stability concerns.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 17 August 2026
New clinical data from Verb Biotics substantiates its oat-based postbiotic, Keystone, as an effective ingredient for modulating gut health and emotional well-being. A four-week, randomised, double-blind, placebo-controlled trial involving healthy adults demonstrated significant enrichment of beneficial gut microbiota, a reduction in pro-inflammatory biomarkers, and marked improvements in emotional wellness. This provides a robust scientific foundation for integrating postbiotics into advanced supplement formulations targeting the gut-brain axis.
The study specifically reported the enrichment of 33 beneficial microbial species and a reduction in 38 taxa associated with gastrointestinal distress. Mechanistically, Keystone operates by enhancing gut barrier function, modulating immune responses, and supporting keystone gut bacteria without introducing exogenous organisms. Crucially, the trial also noted decreased levels of the inflammatory cytokine IL-8 and the stress hormone cortisol, directly correlating with improved emotional states. For brand owners, this offers a compelling, dual-action ingredient: supporting gut resilience while simultaneously impacting mood and stress indicators.
As consumer demand for science-backed, natural solutions for mental wellness and gut health continues to surge, postbiotics represent a critical evolution in the microbiome supplement category. Unlike probiotics, their non-living nature offers superior stability, extended shelf life, and simplifies manufacturing processes, reducing the need for costly cold chain storage and specialized handling. This allows for broader application in diverse product formats, from capsules to functional foods, enhancing market accessibility and formulation flexibility for contract manufacturers and brand owners.
What this means for United Kingdom
UK brand owners can strategically position products featuring Keystone to address both gut health and mental wellness, leveraging MHRA-compliant claims around 'improved emotional wellness' or 'stress management'. Procurement teams should evaluate Keystone against existing probiotic supply chains for potential cost savings up to 15% on storage and distribution due to enhanced stability. Manufacturers must update reformulation windows to integrate this ingredient, targeting Q1 2027 launches to capitalise on growing consumer demand for stable microbiome solutions. This presents a competitive advantage in a market increasingly scrutinising ingredient efficacy and supply chain reliability.
The move towards advanced microbiome modulators like postbiotics signals a maturation of the supplement market. Manufacturers are increasingly seeking ingredients that offer both clinical efficacy and manufacturing ease. This data provides a strong impetus for product development teams to explore postbiotic integration, potentially offering a competitive edge in a crowded market where consumer trust is built on demonstrable benefits and ingredient transparency.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.